July 23, 2007 - BMEYE recently announced CE Mark approval of Nexfin, their newly developed line of reportedly accurate and easy to use hemodynamic monitors. The Nexfin monitors provide accurate and easy to use continuous non-invasive blood pressure and cardiac output monitoring.
"BMEYE was established to develop and market innovative technology that will transform the practice of medicine in hemodynamic patient monitoring. We are pleased and gratified by the CE Mark approval enabling us to market the Nexfin to cardiologists and any clinician who needs to measure continuous non-invasive blood pressure and cardiac output easily and accurately", said Bill Bednarski, CEO of BMEYE. "The Nexfin is cost effective and will significantly improve patient care."
BMEYE, based in Amsterdam and St. Louis, develops and markets innovative medical technology with broad applications in a variety of clinical settings.
The focus of BMEYE is on accurate and easy to use non-invasive hemodynamic monitoring. The Nexfin family of monitors use an easy to apply finger sensor to produce accurate continuous non-invasive blood pressure and cardiac output data displayed on an intuitive touchscreen.
For more information: www.bmeye.com